Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,420 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation and Loss in Eyes with Geographic Atrophy.
Ehlers JP, Cetin H, Amine R, Matar K, Indurkar A, Mamone J, Della Vecchia L, Tang A, Reese J, Luo D, Abulon DJK, Talcott KE. · Ophthalmology · 2026 · cited 1 timesclinical trial, phase iii, clinical trial, phase ii
- Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial.
Boyer DS, Saad L, Washington I, Melamud A, Graham KB, O'Malley AE, DeBartolomeo GM, Jiang H, Harris LD, Kay CN, Ferrone PJ, Khan S, SAGA Study Team. · Ophthalmol Retina · 2026 · cited 0 timesmulticenter study, randomized controlled trial
- Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE.
Dhoot DS, Singerman LJ, Ferrone PJ, Wykoff CC, Goldberg RA, Guymer RH, Kim EL, Maccumber MW, Maia A, Yu S, Yemanyi F, Coughlin BA, Baumal CR, Holz FG, OAKS, DERBY, AND GALE INVESTIGATORS. · Am J Ophthalmol · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Vision-Related Quality of Life in Geographic Atrophy: Association with Topographic Lesion Distribution.
Anegondi N, Lam D, Guymer RH, Steffen V, Cukras CA, Ferrara D, Wu Z. · Ophthalmology · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Longitudinal Prediction of Retinal Sensitivity Based on Disease Progression Quantified From Optical Coherence Tomography in Geographic Atrophy.
Birner K, Mai J, Boryshchuk D, Frommlet F, Schwartz R, Schürer-Waldheim S, Leingang O, Dieter-Vogl W, Schmidt-Erfurth U. · Invest Ophthalmol Vis Sci · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD.
Holz FG, Le Mer Y, Muqit MMK, Hattenbach LO, Cusumano A, Grisanti S, Kodjikian L, Pileri MA, Matonti F, Souied E, Stanzel BV, Szurman P, Weber M, Bartz-Schmidt KU, Eter N, Delyfer MN, Girmens JF, van Overdam KA, Wolf A, Hornig R, Corazzol M, Brodie F, Olmos de Koo L, Palanker D, Sahel JA. · N Engl J Med · 2026 · cited 36 timesOpen accessclinical trial, multicenter study
- Exploring Trial Endpoints in Geographic Atrophy Based on Localized Functional Changes in Microperimetry and AI-Quantified OCT Biomarkers.
Birner K, Mai J, Boryshchuk D, Frommlet F, Enzendorfer ML, Schürer-Waldheim S, Gumpinger M, Vogl WD, Leingang O, Sacu S, Schmidt-Erfurth U. · Invest Ophthalmol Vis Sci · 2026 · cited 2 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Detection and Management of Geographic Atrophy Secondary to Age-Related Macular Degeneration Using Noninvasive Retinal Images and Artificial Intelligence: Systematic Review.
Shi N, Li J, Shang M, Zhang W, Xu K, Li Y, Liang L. · J Med Internet Res · 2025 · cited 2 timesOpen accesssystematic review, review-article
- Comparison of Multiple Techniques for Measuring Geographic Atrophy: A Systematic Review and Network Meta-Analysis.
Rassi TNO, Binotti WW, Danielli EMC, Fernandes SP, Machado DCS, Amaral DC, Novais EA, Louzada RN, Penha FM, Maia M, Duker JS. · Ophthalmic Surg Lasers Imaging Retina · 2025 · cited 0 timescomparative study, systematic review
- Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.
Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG, GATHER2 Trial Investigators. · Ophthalmology · 2026 · cited 2 timesclinical trial, phase iii, research support, non-u.s. gov't
- Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials.
Anegondi N, Steffen V, Sadda SR, Schmitz-Valckenberg S, Tufail A, Csaky K, Lad EM, Kaiser PK, Ferrara D, Chakravarthy U. · Ophthalmology · 2025 · cited 15 timesclinical trial, phase iii, research support, non-u.s. gov't
- Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.
Mai J, Reiter GS, Riedl S, Vogl WD, Sadeghipour A, McKeown A, Foos E, Bogunovic H, Schmidt-Erfurth U. · Invest Ophthalmol Vis Sci · 2025 · cited 2 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Outer Retinal Tubulation in Geographic Atrophy.
Hatcher KA, Shah BK, Burch M, Kondapalli SSA, Baumal CR. · Ophthalmic Surg Lasers Imaging Retina · 2024 · cited 4 timesclinical trial, phase ii, research support, non-u.s. gov't
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.
Wykoff CC, Holz FG, Chiang A, Boyer D, Dhoot DS, Loewenstein A, Mones J, Heier J, Abbey AM, Singerman LJ, Vajzovic L, Lin J, Li C, Vilupuru A, Baumal CR, OAKS, DERBY, and GALE Investigators. · Am J Ophthalmol · 2025 · cited 12 timesclinical trial, phase iii, multicenter study
- Structure-Function Relationships in Geographic Atrophy Based on Mesopic Microperimetry, Fundus Autofluorescence, and Optical Coherence Tomography.
Mukherjee S, Arunachalam T, Duic C, Abraham M, Orndahl C, Menezes S, Agrón E, Pfau M, de Silva T, Bailey C, Thavikulwat AT, Bellur S, Sadda SR, Chew EY, Jeffrey BG, Wong WT, Keenan TDL. · Transl Vis Sci Technol · 2025 · cited 7 timesOpen accessclinical trial, phase ii
- Outer Retinal Tubulation and Vision in Geographic Atrophy: A Natural History Analysis From the Phase 3 OAKS and DERBY Trials.
Hatcher KA, Shah BK, Yu S, Baumal CR, Sadda S. · Ophthalmic Surg Lasers Imaging Retina · 2025 · cited 1 timesclinical trial, phase iii, multicenter study
- Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham.
Crass RL, Prem K, Gaudreault F, Lusk E, Ribeiro R, Chapel S, Baumal CR. · CPT Pharmacometrics Syst Pharmacol · 2025 · cited 4 timesOpen accessclinical trial, phase iii, clinical trial, phase ii
- Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study.
Goldberg RA, Boyer DS, Holz FG, MacCumber MW, Garg SJ, Brown DM, Lad EM, Steinle N, Rishi PS, Pearce I, Ach T, Ribeiro R, Li C, Jones D, Tsuboi M, Ferrone PJ, Baumal CR, Wykoff CC. · Ophthalmic Surg Lasers Imaging Retina · 2025 · cited 3 timesclinical trial, phase iii, research support, non-u.s. gov't
- Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy.
Bressler NM, Freund KB, Bakri SJ, Kim JE, Ferrara D, Brittain C, Pickthorn K, Lin H, Sun C, Martin J. · JAMA Ophthalmol · 2024 · cited 0 timesOpen accessbrief-report, multicenter study
- Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ, Bagga P, Naik G, Glinton S, Faes L, Liefers B, Lima R, Wignall G, Keane PA, Ioannidou E, Ribeiro Reis AP, McKeown A, Scheibler L, Patel PJ, Moghul I, Pontikos N, Balaskas K. · JAMA Ophthalmol · 2024 · cited 27 timesOpen accessclinical trial, phase iii, multicenter study
- A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan.
Patel NA, Hoyek S, Al-Khersan H, Yannuzzi NA, Smiddy WE. · Ophthalmol Retina · 2024 · cited 7 timescomparative study, randomized controlled trial
- Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Eichenbaum DA, Holekamp N, Khanani AM, Pieramici D, Hershberger V, Sheth V, Brunstein F, Ma L, Zou Y, Indjeian VB, Dere R, Maia M, Hsu JC, Gao SS, Yaspan B, Willis JR, Wiley H, Lai P, Chen H. · Am J Ophthalmol · 2025 · cited 6 timesclinical trial, phase ii, research support, non-u.s. gov't
- Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT.
Schmidt-Erfurth U, Mai J, Reiter GS, Riedl S, Vogl WD, Sadeghipour A, McKeown A, Foos E, Scheibler L, Bogunovic H. · Ophthalmology · 2025 · cited 37 timesclinical trial, phase iii, research support, non-u.s. gov't
- Progression Rate of Macular Retinal Pigment Epithelium Atrophy in Geographic Atrophy and Selected Inherited Retinal Dystrophies. A Systematic Review and Meta-Analysis.
Bassil FL, Colijn JM, Thiadens AAHJ, Biarnés M. · Am J Ophthalmol · 2025 · cited 7 timesmeta-analysis, systematic review
- Determinants of Four-Year Visual Acuity Loss in Geographic Atrophy: An Analysis of Age-Related Eye Disease Study and Age-Related Eye Disease Study 2.
Shen LL, Kaiser PK, Liu J, Stewart JM, Heyang M, Keenan TDL, Sunness JS, Rosenfeld PJ, Chew EY, Del Priore LV. · Ophthalmology · 2025 · cited 11 timesresearch support, non-u.s. gov't, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.